Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Burstein HJ, et al. Among authors: winer ep. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504. doi: 10.1016/j.ijrobp.2005.07.975. Epub 2005 Oct 21. Int J Radiat Oncol Biol Phys. 2006. PMID: 16243442 Clinical Trial.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. Winer EP, et al. J Clin Oncol. 2002 Aug 1;20(15):3317-27. doi: 10.1200/JCO.2002.06.020. J Clin Oncol. 2002. PMID: 12149306 Review.
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. Chlebowski RT, et al. Among authors: winer ep. J Clin Oncol. 2002 Aug 1;20(15):3328-43. doi: 10.1200/JCO.2002.06.029. J Clin Oncol. 2002. PMID: 12149307 Review.
Lumping versus splitting: the splitters take this round.
Bunnell CA, Winer EP. Bunnell CA, et al. Among authors: winer ep. J Clin Oncol. 2002 Sep 1;20(17):3576-7. doi: 10.1200/JCO.2002.06.157. J Clin Oncol. 2002. PMID: 12202656 No abstract available.
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Burstein HJ, et al. Among authors: winer ep. J Clin Oncol. 2003 Jan 1;21(1):46-53. doi: 10.1200/JCO.2003.03.124. J Clin Oncol. 2003. PMID: 12506169 Clinical Trial.
574 results